Effects of Ensitrelvir on the Pharmacokinetics of Combined Oral Contraceptives (Ethinyl Estradiol/Drospirenone) in Healthy Adult Women: A Phase 1 Fixed-Sequence, Multiple-Dose, Drug-Drug Interaction S
4 hours ago
- #oral contraceptives
- #drug-drug interaction
- #clinical trial
- Ensitrelvir, a COVID-19 antiviral, was studied for interaction with combined oral contraceptives (ethinyl estradiol/drospirenone) in healthy women.
- Co-administration increased drospirenone exposure by up to 80% but kept it within a safe range, with no clinically meaningful effect on ethinyl estradiol.
- The drug combination was well-tolerated with no severe adverse events, supporting co-use without dose adjustments.
- Findings are expected to apply to other contraceptive progestins due to shared metabolic pathways.